ICCC compared with IDXX: revenue, margins and what each company keeps, and the suppliers and customers both name

ICCCImmucell Corp

Mkt capRevenueRevenue

IDXXIdexx Laboratories Inc

Mkt capRevenueRevenue

Compare

ICCCImmucell Corp

IDXXIdexx Laboratories Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ICCC2 of 4 reports

Reportimpliedrealized× implied

Oct 13 '26—▲+12.40%—

Q2 FY26—▼−7.80%—

IDXX

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±8.6%▲+21.85%×2.55

Q2 FY26±8.4%▲+3.57%×0.43

= impliedICCC realized, solidIDXX realized, hatchedOne scale, both sides: full bar = 22%× = |realized| ÷ impliedspan: ICCC 60d · IDXX 273dSource: market data

Q1 FY26

±8.0%

▼−0.03%

×0.00

Feb 2 '26±8.9%▼−4.60%×0.52

ICCCImmucell Corp

10.40▲+4.52%· post 10.00

Mkt cap$90.1MRevenue$7MQ2 FY26Revenue$28MFY25

IDXXIdexx Laboratories Inc

676.84▲+0.91%· post 677.73

ClosedNov 6 '26

Mkt cap$53.3BRevenue$1.2BQ3 FY26Revenue$4.3BFY25

Compare

ClosedNov 6 '26

ICCCImmucell Corp

IDXXIdexx Laboratories Inc

10.40▲+4.52%post 10.00

Price

676.84▲+0.91%post 677.73

$90.1M

Mkt cap

$53.3B

Q2 FY26$7M

Revenue

$1.2BQ3 FY26

FY25$28M

Revenue

$4.3BFY25

ICCC10.40▲+4.52%vsIDXX676.84▲+0.91%ClosedNov 6 '26